focus -WSS

focus

author：knowledge 2025-09-06 04:27:20 - browse：61864

Peter Marks. -- health coverage from STAT — Peter Marks, Director of the Center for Biologics Evaluation and Research at the Food and Drug Administration. Susan Walsh-Pool/Getty Images

Peter Marks wants drug developers to ask more stupid questions.

It’s part of the top Food and Drug Administration official’s plan to reinvigorate gene therapy, a field that has struggled despite significant technological advances. Some companies are shelving programs or going out of business, even when they have promising data.

The problems are numerous: The diseases are often exceptionally rare, limiting the potential market. Manufacturing at commercial quality is complex and expensive. Proving a drug works can be difficult, because there may be too few patients to run a traditional randomized study.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Roivant's CEO is a star, but biotech's black hole persists

WSS

How the first Native Hawaiian psychiatrist helped diversify medicine

Intellia plays down concerns on accidental germline transmission

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Smaller biotechs seek to piggyback on weight loss drug boom

ADCs take center stage as promising cancer treatments

Health tech investors get more selective as pandemic boom fades

leisure time

focus

leisure time

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Can U.S. cancer drug shortages be fixed?

Drug repurposing or repositioning? The language matters

Republicans love RFK Jr. What's that tell us about health in 2024?

Guidelines to prevent youth baseball injuries need more muscle

STAT Summit: Ending the crisis of Black deaths in the U.S.

Anesthesiologist group: stop taking Ozempic before surgery

Health officials lay out plans to cope with respiratory virus season

How to save PrEP access — and even expand it

Smaller biotechs seek to piggyback on weight loss drug boom

leisure time

How the drug

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

Listen: Vivek Ramaswamy's star turn & leaky drug data

As obesity drug market grows, telehealth companies court payers

Study on Amgen’s bispecific immunotherapy produces positive data

focus

focus

leisure time

leisure time